TriApex

TriApex, founded in 2008, is a specialized Contract Research Organization (CRO) based in Nanjing, China. The firm provides disease-oriented, one-stop R&D solutions for global pharmaceutical enterprises and research institutions. By focusing on high-efficiency drug development workflows, TriApex supports the entire lifecycle of pharmaceutical innovation, positioning itself as a critical partner in the global life sciences supply chain.

The organization maintains a robust operational footprint with 1,000-5,000 employees dedicated to clinical and laboratory research services. Meet TriApex's team to understand the technical expertise driving their service delivery and organizational structure. Their operational model emphasizes precision and regulatory compliance, ensuring that complex research requirements are met with high-quality data outputs. The company operates from a single primary location in the Jiangbei New Area of Nanjing, leveraging regional infrastructure to facilitate international collaboration.

TriApex demonstrates significant market presence with annual revenue reaching $211.3M. The company has successfully secured strategic capital, including a $3.5M financing round in May 2023 involving investors such as DSP Mutual Fund, Anchorage Capital Partners, and Massachusetts Mutual Life Insurance. This financial stability supports their ongoing investment in laboratory capabilities and service expansion. Explore financial highlights to review detailed performance metrics and funding history. The firm continues to scale its service offerings, maintaining a competitive edge in the business services sector through specialized CRO expertise and consistent operational growth.